Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-week efficacy and safety of D/C/F/TAF versus darunavir/cobicistat + emtricitabine/tenofovir disoproxil fum...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors: Bruce Rashbaum, Christoph D. Spinner, Cheryl McDonald, Cristina Mussini, John Jezorwski, Donghan Luo, Erika Van Landuyt, Kimberley Brown, Eric Y. Wong
Format: Article
Sprog:English
Udgivet: Taylor & Francis Group 2019-01-01
Serier:HIV Research & Clinical Practice
Fag:
hiv-1
darunavir
antiretroviral
protease inhibitor
single-tablet regimen
tenofovir alafenamide
treatment initiation
Online adgang:http://dx.doi.org/10.1080/15284336.2019.1608714

Internet

http://dx.doi.org/10.1080/15284336.2019.1608714

Lignende værker